Thomas Zander

机构：University of Cologne, Düsseldorf University Hospital, University Hospital Cologne, Heinrich Heine University Düsseldorf · ORCID：0000-0002-4266-6818

发表论文 428 篇 · 总被引 27440 次 · h-index 67

代表论文

• Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. (2025 · Journal of Clinical Oncology · 被引 50)
• Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial (2025 · Nature Medicine · 被引 25)
• The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma (2025 · Scientific Reports · 被引 11)
• AI-based tumor-stroma ratio quantification algorithm: comprehensive evaluation of prognostic role in primary colorectal cancer (2025 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 被引 8)
• Ianalumab plus Eltrombopag in Immune Thrombocytopenia (2025 · New England Journal of Medicine · 被引 5)
• Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy (2025 · International Journal of Cancer · 被引 5)